SNMMI Consensus Statement on Patient Selection and Appropriate Use of ¹⁷⁷Lu-PSMA-617 Radionuclide Therapy

Affiliations

• ¹ Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; thomas.hope@ucsf.edu.
• ² University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota.
• ³ Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
• ⁴ Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
• ⁵ Department of Radiology, University of Washington, Seattle, Washington.
• ⁶ Department of Radiology, Brigham and Women's Hospital, and Department of Imaging, Dana-Farber Cancer Institute, Boston, Massachusetts.
• ⁷ Banner M.D. Anderson Cancer Center, Phoenix, Arizona.
• ⁸ Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
• ⁹ Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, New York.
• ¹⁰ Department of Medicine, Weill Cornell Medical College, New York, New York.
• ¹¹ Mayo Clinic, Rochester, Minnesota; and.
• ¹² Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.